Litigation Details for Astellas Pharma Inc. v. Ascent Pharmaceuticals, Inc. (D. Del. 2024)

Astellas Pharma Inc. v. Ascent Pharmaceuticals, Inc. (D. Del. 2024)

Docket		Date Filed	2024-09-27
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Joseph F. Bataillon
Jury Demand	None	Referred To	Eleanor G. Tennyson
Patents	10,842,780; 11,707,451; 12,059,409; 12,097,189
Link to Docket	External link to docket

Details for Astellas Pharma Inc. v. Ascent Pharmaceuticals, Inc. (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-09-27				External link to document

Litigation Summary & IP Analysis: Astellas Pharma Inc. v. Ascent Pharmaceuticals, Inc. (1:24-cv-01084)

Last updated: July 16, 2026

Astellas Pharma Inc. is the plaintiff in Astellas Pharma Inc. v. Ascent Pharmaceuticals, Inc., case number 1:24-cv-01084, filed in 2024 (U.S. District Court). The matter concerns patent-driven generic market entry under the Hatch-Waxman framework, with Ascent’s proposed product at issue. The case posture and substantive patent claims cannot be summarized accurately here without reliable access to the docket record, complaint, responsive filings, and the asserted patents and FDA Orange Book listing identifiers.

What patents are asserted in Astellas v. Ascent (1:24-cv-01084)?

Featured snippet answer: The asserted patent list and the specific claims asserted are determined by the complaint and any amended pleadings in 1:24-cv-01084. These details are not provided in the prompt.

Which patent numbers are listed in the complaint?

The answer requires the complaint’s “patents-in-suit” section and any attachments that identify:

• U.S. patent numbers asserted
• publication/patent application numbers (if relevant)
• claim numbers asserted under each patent
• theories pled (infringement, invalidity defenses, non-infringement)

Are any patents added or narrowed after filing?

This requires review of:

• amended complaints
• amended infringement contentions
• claim construction orders (if issued)
• stipulations narrowing issues

What is the core Hatch-Waxman theory in this case?

Featured snippet answer: Hatch-Waxman patent litigation typically turns on whether a generic manufacturer’s “Paragraph IV” certification and proposed labeling/capsule/tablet composition infringe asserted patents and whether those patents are valid and enforceable. The specific certifications and product description for Ascent are not included in the prompt.

Is the case tied to Orange Book “listed drug” and FDA certification?

To map the litigation to FDA status, the record must identify:

• the listed drug (NDC or proprietary name)
• the reference listed drug (RLD)
• the FDA filing type (ANDA or 505(b)(2))
• the Paragraph IV certification element(s) and carve-outs

What relief is sought by Astellas?

A complete, accurate summary must state whether Astellas seeks:

• injunctive relief under 35 U.S.C. § 271(e)(4)
• declaratory relief on invalidity/non-infringement
• attorney fees under 35 U.S.C. § 285 (if pled)

What is the procedural posture in 1:24-cv-01084?

Featured snippet answer: Procedural posture must be derived from docket events (motions to dismiss, Markman schedule, claim construction, summary judgment, trial dates, and any settlement or consent judgment). No docket dates or motion outcomes are provided in the prompt.

Key milestones to extract from the docket

A litigation-grade timeline requires exact dates for:

• complaint filing date
• service and answer deadline
• motion practice (dismissal, stay, discovery, protective order)
• claim construction schedule (Markman)
• any stipulations or amended scheduling orders

Has the case been stayed for FDA/ANDA timelines?

Stays are common where:

• related prosecution or appeals are ongoing
• co-pending litigation affects exclusivity or ANDA approval timing
• the parties enter settlement or agree to specific entry triggers

How does claim construction affect infringement and validity?

Featured snippet answer: Claim construction can decide whether Ascent’s proposed product maps onto the asserted claim limitations and whether prior art anticipates or renders claims obvious. Claim terms and any construed language are not included in the prompt.

Which claim terms are typically outcome-determinative?

In Hatch-Waxman pharma cases, courts commonly construe:

• composition parameters (e.g., ratio ranges, polymorph selection, particle size)
• method steps (timing, conditions, process parameters)
• functional limitations tied to bioavailability or stability
• formulation and manufacturing method limitations

What happens if the court construes claims narrowly?

To analyze directionally, the record must include:

• Markman order text
• infringement chart mappings by both sides
• the court’s interpretation of disputed terms

What Paragraph IV challenge(s) is Ascent making?

Featured snippet answer: A Paragraph IV filing usually asserts that at least one of the patents in-suit is invalid, unenforceable, or not infringed. The specific certifications and the basis are not provided in the prompt.

Which invalidity grounds are alleged?

Patent invalidity defenses often include:

• anticipation under 35 U.S.C. § 102
• obviousness under 35 U.S.C. § 103
• lack of written description or enablement under § 112(a)
• indefiniteness under § 112(b)
• improper inventorship or inequitable conduct (in some cases)

Is there a non-infringement or “design-around” argument?

A robust summary requires identifying:

• Ascent’s proposed manufacturing or formulation differences
• label carving or section viii changes to avoid infringement
• evidence cited (comparative examples, testing reports)

What product and formulation is at issue in the litigation?

Featured snippet answer: The drug product identity (active ingredient, dosage form, strength, and any polymorph/formulation) must be stated to analyze infringement. These facts are not included in the prompt.

What dosage forms are implicated?

Astellas/Ascent cases can involve:

• tablets vs capsules
• extended-release vs immediate-release
• injectables vs oral solids
• specific strengths tied to the ANDA

Is the dispute about a method-of-use, composition, or both?

Different claim types drive different analyses:

• composition/formulation patents focus on structure and parameters
• method-of-use patents focus on prescribing or administration steps
• device or combination claims change the label and product mapping

Which court and judge handle the case?

Featured snippet answer: The presiding judge and court division are essential for procedural and schedule analysis. That information is not included in the prompt.

Why judge identity matters for a patent case summary

Judge assignment can correlate with:

• claim construction scheduling habits
• typical approach to discovery disputes
• motion-to-dismiss and transfer likelihood
• speed to Markman and summary judgment

What settlement signals or entry-risk outcomes exist?

Featured snippet answer: Any settlement or licensing agreement terms, including agreed launch dates, 30-month stay status impacts, and design-around carve-outs, must be taken from docket filings or joint status reports. No such details are provided in the prompt.

Is there a consent judgment or dismissal?

Settlement can appear as:

• stipulation of dismissal with prejudice
• dismissal without prejudice pending license conditions
• consent judgment establishing launch and/or royalty structure

Does the case affect ANDA approval or “at-risk” launch?

A full analysis requires:

• whether the ANDA is approved yet
• whether exclusivity/automatic stay bars FDA approval timing
• whether injunction issues deter launch pre-approval

How strong is the patent estate for Astellas against Ascent’s likely design space?

Featured snippet answer: Strength depends on the asserted patents’ expiration, prosecution history, claim breadth, and prior art record. None of these inputs are included.

How many patents are typically in-suit in this posture?

This must be derived from the complaint’s patent list and any later amendments.

What is the expiration and projected generic entry window?

A calculation needs:

• earliest effective filing dates
• patent expiration dates
• any PTA/PTE
• term adjustments and disclaimers
• exclusivity barriers (Orange Book, market exclusivity)

How does this case compare with other Astellas generic challenges?

Featured snippet answer: A comparison requires identifying:

• the same Astellas product category
• similar Ascent counterparties
• recurrent patent types (formulation vs method-of-use)
• consistent strategic defenses (obviousness, lack of enablement) Those facts are not provided in the prompt.

Key Takeaways

• Case identification: Astellas Pharma Inc. v. Ascent Pharmaceuticals, Inc., 1:24-cv-01084.
• Missing for a litigation-grade summary: asserted patent numbers, claims, Orange Book/RLD link, Paragraph IV certifications, docket events (motions and dates), and any settlement or injunction outcomes are not included in the prompt.
• Actionable conclusion: a business-usable litigation analysis cannot be produced accurately without those record-specific facts.

FAQs

1) What patents are included as “patents-in-suit” in 1:24-cv-01084?
Not specified in the prompt.

2) Is Ascent’s filing an ANDA with Paragraph IV certifications?
Not specified in the prompt.

3) Has the court issued a Markman claim construction order?
Not specified in the prompt.

4) What is the current status: pending, stayed, or settled?
Not specified in the prompt.

5) What does the case mean for FDA approval timing and generic launch risk?
Not specified in the prompt.

References

No sources cited because the prompt does not include the docket, complaint, or any text suitable for a citation-backed litigation summary.